Kintegral Advisory LLC Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Kintegral Advisory LLC lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,928 shares of the pharmaceutical company’s stock after selling 323 shares during the quarter. Kintegral Advisory LLC’s holdings in Vertex Pharmaceuticals were worth $2,790,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Foundations Investment Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 11.3% during the 3rd quarter. Foundations Investment Advisors LLC now owns 849 shares of the pharmaceutical company’s stock valued at $395,000 after purchasing an additional 86 shares during the last quarter. International Assets Investment Management LLC boosted its stake in Vertex Pharmaceuticals by 74,015.5% during the third quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company’s stock worth $150,977,000 after buying an additional 324,188 shares during the period. Global Trust Asset Management LLC increased its position in Vertex Pharmaceuticals by 26.9% during the third quarter. Global Trust Asset Management LLC now owns 1,037 shares of the pharmaceutical company’s stock valued at $482,000 after acquiring an additional 220 shares during the last quarter. Dakota Wealth Management raised its stake in shares of Vertex Pharmaceuticals by 13.3% in the third quarter. Dakota Wealth Management now owns 34,393 shares of the pharmaceutical company’s stock valued at $15,995,000 after acquiring an additional 4,042 shares during the period. Finally, Schmidt P J Investment Management Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 10.0% in the 3rd quarter. Schmidt P J Investment Management Inc. now owns 2,021 shares of the pharmaceutical company’s stock worth $940,000 after acquiring an additional 183 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $484.24 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The business has a fifty day moving average of $436.05 and a two-hundred day moving average of $460.70. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on VRTX. Barclays upped their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. StockNews.com cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. Citigroup started coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target on the stock. BMO Capital Markets dropped their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a report on Friday, December 20th. Finally, Stifel Nicolaus increased their target price on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $505.61.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.